Lan KH - Search Results

1

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. Nagata Y, et al. Among authors: lan kh. Cancer Cell. 2004 Aug;6(2):117-27. doi: 10.1016/j.ccr.2004.06.022. Cancer Cell. 2004. PMID: 15324695 Free article.

2

Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis.

Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D. Tan M, et al. Among authors: lan kh. Mol Cell. 2002 May;9(5):993-1004. doi: 10.1016/s1097-2765(02)00510-5. Mol Cell. 2002. PMID: 12049736 Free article.

3

Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.

Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D. Lee S, et al. Among authors: lan kh. Cancer Res. 2002 Oct 15;62(20):5703-10. Cancer Res. 2002. PMID: 12384528

4

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.

Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D. Zhou X, et al. Among authors: lan kh. Clin Cancer Res. 2004 Oct 15;10(20):6779-88. doi: 10.1158/1078-0432.CCR-04-0112. Clin Cancer Res. 2004. PMID: 15501954

5

ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.

Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, Yu D. Tan M, et al. Among authors: lan kh. Cancer Res. 2005 Mar 1;65(5):1858-67. doi: 10.1158/0008-5472.CAN-04-2353. Cancer Res. 2005. PMID: 15753384

6

Mechanisms of trastuzumab resistance and their clinical implications.

Lan KH, Lu CH, Yu D. Lan KH, et al. Ann N Y Acad Sci. 2005 Nov;1059:70-5. doi: 10.1196/annals.1339.026. Ann N Y Acad Sci. 2005. PMID: 16382045 Review.

7

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D. Lu CH, et al. Among authors: lan kh. Clin Cancer Res. 2007 Oct 1;13(19):5883-8. doi: 10.1158/1078-0432.CCR-06-2837. Clin Cancer Res. 2007. PMID: 17908983

8

14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival.

Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, Hittelman W, Hung MC, Yu D. Neal CL, et al. Among authors: lan kh. Cancer Res. 2009 Apr 15;69(8):3425-32. doi: 10.1158/0008-5472.CAN-08-2765. Epub 2009 Mar 24. Cancer Res. 2009. PMID: 19318578 Free PMC article.

9

Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.

Tan M, Lan KH, Yao J, Lu CH, Sun M, Neal CL, Lu J, Yu D. Tan M, et al. Among authors: lan kh. Cancer Res. 2006 Apr 1;66(7):3764-72. doi: 10.1158/0008-5472.CAN-05-2747. Cancer Res. 2006. PMID: 16585203

10

Identification of differentially expressed genes in nasopharyngeal carcinoma by means of the Atlas human cancer cDNA expression array.

Xie L, Xu L, He Z, Zhou W, Wang L, Zhang L, Lan K, Ren C, Liu W, Yao K. Xie L, et al. J Cancer Res Clin Oncol. 2000 Jul;126(7):400-6. doi: 10.1007/pl00008488. J Cancer Res Clin Oncol. 2000. PMID: 10929762

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

111 results

Search Page

Filters